Contract facts
FederalNo full NAICS 541714 intel page yet. Browse NAICS intelligence
NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY is a federal award for Defense Health Agency held by Eitr Biologics, Inc. Estimated value $270K ($270K obligated). Current period of performance ends Mar 31, 2027. Place of performance: SAN DIEGO CA.
Recompete timing
PublicCurrent PoP ends Mar 31, 2027 (222 days remaining). Agencies typically plan 12–18 months ahead — at 7.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordEitr Biologics, Inc — $37.9M obligated across 9 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT942626FE033?
HT942626FE033 (NOVEL bispecific BROAD spectrum nanobody) is a Defense Health Agency award with a potential value of $270K, currently held by Eitr Biologics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded HT942626FE033?
Defense Health Agency awarded HT942626FE033 to Eitr Biologics, Inc (potential $270K).
Who is the incumbent on HT942626FE033?
Eitr Biologics, Inc is the incumbent with $37.9M across 9 related awards in SCOUT’s public footprint. The current period of performance ends Mar 31, 2027.
When does Eitr Biologics, Inc’s HT942626FE033 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.